GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3381)

  • GC71968 structure
    GC71968Celosin K
    CAS: 1950579-53-9
    Purity: >99.00%

    Celosin K(化合物8)は青藤種子から分離することができる。

  • GC71997 structure
    GC71997Alphitolic acid
    CAS: 19533-92-7
    Purity: >98.00%

    Alphitolic acidはlupane骨格を持つ五環式トリテルペノイドであり、抗炎症と細胞毒性活性を示す。

  • GC72001 structure
    GC72001Phellamurin
    CAS: 52589-11-4

    Phellamurinは、phellodendron amurenseの葉に由来する植物フラボノン配糖体で、腸内p-糖タンパク質を阻害する。

  • GC72012 structure
    GC72012Dehydrocrenatidine
    CAS: 65236-62-6
    Purity: >98.00%

    Dehydrocrenatidineは天然アルカロイドであり、特定のJAK阻害剤である。

  • GC72018 structure
    GC72018Goniothalamin
    CAS: 17303-67-2
    Purity: >98.00%

    Goniothalamin(GTN)は抗がん、抗炎症、免疫抑制特性を有するスチリルラクトンである。

  • GC72054 structure
    GC72054Obovatol
    CAS: 83864-78-2
    Purity: >99.00%

    Obovatolは厚い朴葉から分離されたビフェニルエーテルリグニンである。

  • GC72061 structure
    GC72061β-Phellandrene
    CAS: 555-10-2
    Purity: >99.50%

    β-Phellandreneは岩骨から得られた。

  • GC72103 structure
    GC72103Kp7-6
    CAS: 629628-53-1
    Purity: >98.00%

    Kp7-6はfasの模倣ペプチドであり、fas / faslアンタゴニストである。

  • GC72146 structure
    GC72146WP9QY TFA
    Purity: >99.00%

    WP9QY TFATNF-aアンタゴニストは生物活性ペプチドである。

  • GC72147 structure
    GC72147Mca-YVADAP-Lys(Dnp)-OH TFA
    Purity: >98.00%

    Mca-YVADAP-Lys(Dnp)-OH TFAは、カスパーゼ1およびアンジオテンシン変換酵素2 ace2のフッ素生成基質である。

  • GC72183 structure
    GC72183[D-Leu-4]-OB3
    CAS: 289056-32-2
    Purity: >99.00%

    [D-Leu-4]-OB3炎症誘発性、増殖性および転移性遺伝子およびpd-l1発現の発現を阻害する。

  • GC72186 structure
    GC72186WLSEAGPVVTVRALRGTGSW
    CAS: 771479-86-8
    Purity: >96.00%

    WLSEAGPVVTVRALRGTGSWは心筋細胞特異性ペプチドである。

  • GC72191 structure
    GC72191Pep19-2.5
    CAS: 1322711-38-5
    Purity: >98.00%

    Pep19-2.5は、細胞内エンドトキシン伝達カスケードを遮断する合成・抗毒素ペプチドである。

  • GC72216 structure
    GC72216(Gly14)-Humanin (human) (acetate)
    Purity: >98.00%

    (Gly14)-Humanin (human) (acetate)はHumaninの類似体であり、14番目のアミノ酸セリンがグリシン(Gly)で置換されている。

  • GC72251 structure
    GC72251Tripeptide-32
    CAS: 1185583-20-3
    Purity: >99.00%

    Tripeptide-32はアンチエイジング作用を持つ生物活性ペプチドであり、化粧品成分として報告されている。

  • GC72318 structure
    GC72318Tulisokibart
    CAS: 2648504-55-4
    Purity: 95.00%

    Tulisokibart (PRA023)は人間に影響されIgG1 -κモノクローナル抗体照準をTNFSF15 / TL1A。

  • GC72319 structure
    GC72319Atrosab
    CAS: 1365659-05-7
    Purity: >96.00%

    Atrosabはヒト化IgG 1拮抗性抗TNFR 1抗体である。

  • GC72337 structure
    GC72337Anti-Mouse 4-1BB/CD137 Antibody (3H3)
    Purity: >99.00%

    Anti-Mouse 4-1BB/CD137 Antibody (3H3)は宿主ラット由来の抗マウス4-1 BB IgG 2 a抗体阻害剤である。

  • GC72359 structure
    GC72359Quilizumab
    CAS: 1228538-47-3
    Purity: >96.00%

    Quilizumab(抗ヒトNGcGM 3組換え抗体)はヒト化IgG 1κモノクローナル抗体である。

  • GC72360 structure
    GC72360Ruplizumab
    CAS: 220651-94-5
    Purity: >99.00%

    Ruplizumab(BG 9588)はヒト化モノクローナル抗CD 40 L(TNF受容体)IgG 1κ抗体である。

  • GC72364 structure
    GC72364Toralizumab
    CAS: 252662-47-8
    Purity: 95.00%

    Toralizumab(IDEC-131)は、ヒトγ1重鎖とヒトκ軽鎖からなるCD 40 L(CD 154)に対するヒト化モノクローナル抗体(mAb)である。

  • GC72365 structure
    GC72365Visilizumab
    CAS: 219716-33-3
    Purity: >98.00%

    Visilizumab(抗ヒトCD 3 E組換え抗体)は、ヒト化低Fc受容体結合の抗CD 3モノクローナルIgG 2抗体である。

  • GC72378 structure
    GC72378Neihulizumab
    CAS: 2158362-38-8
    Purity: >98.00%

    Neihulizumab(ALTB-168)は免疫検査点作動性抗体であり、ヒトCD 162(PSGL-1)と結合し、活性化T細胞の低下をもたらす。

  • GC72386 structure
    GC72386Afelimomab
    CAS: 156227-98-4
    Purity: >99.00%

    Afelimomab(MAK 195 F)は抗腫瘍壊死因子F(ab')2モノクローナル抗体断片である。